We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+2.84%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.32B
AUM Growth
-$616M
Cap. Flow
-$442M
Cap. Flow %
-13.32%
Top 10 Hldgs %
35.56%
Holding
123
New
10
Increased
41
Reduced
28
Closed
11

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$31.4M
2
JNJ icon
Johnson & Johnson
JNJ
+$25.3M
3
GPCR icon
Structure Therapeutics
GPCR
+$24.1M
4
UNH icon
UnitedHealth
UNH
+$22.1M
5
LLY icon
Eli Lilly
LLY
+$14.6M

Top Sells

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$99.4M
2
PEN icon
Penumbra
PEN
+$47.9M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$44M
4
BSX icon
Boston Scientific
BSX
+$30.4M
5
IDXX icon
Idexx Laboratories
IDXX
+$30M

Sector Composition

Rank Sector Weight
1 Healthcare 97.3%
2 Consumer Staples 1.87%
3 Industrials 0.25%
4 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
1
DELISTED
Blueprint Medicines
BPMC
$265M 7.98%
2,460,417
-38,031
-2% -$3.81M
UNH icon
2
UnitedHealth
UNH
$382B
$140M 4.22%
275,000
+45,000
+20% +$22.1M
ISRG icon
3
Intuitive Surgical
ISRG
$127B
$133M 4%
298,500
– –
NBIX icon
4
Neurocrine Biosciences
NBIX
$18.2B
$129M 3.9%
940,000
-114,900
-11% -$15.8M
LLY icon
5
Eli Lilly
LLY
$1.08T
$110M 3.31%
121,500
+18,250
+18% +$14.6M
ARGX icon
6
argenx
ARGX
$55.2B
$98.6M 2.97%
229,250
– –
ACHC icon
7
Acadia Healthcare
ACHC
$2.55B
$79.5M 2.39%
1,177,500
– –
RARE icon
8
Ultragenyx Pharmaceutical
RARE
$2.46B
$79.1M 2.38%
1,924,072
+149,134
+8% +$6.37M
EVH icon
9
Evolent Health
EVH
$371M
$78M 2.35%
4,077,500
+90,000
+2% +$2.3M
MDGL icon
10
Madrigal Pharmaceuticals
MDGL
$12.6B
$68.8M 2.07%
245,499
-40,432
-14% -$9.62M
BSX icon
11
Boston Scientific
BSX
$68.4B
$63M 1.89%
817,500
-415,000
-34% -$30.4M
FRPT icon
12
Freshpet
FRPT
$3.04B
$62.1M 1.87%
480,000
-182,500
-28% -$21.9M
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$38.3B
$60.8M 1.83%
250,000
+6,000
+2% +$947K
MIRM icon
14
Mirum Pharmaceuticals
MIRM
$6.56B
$60.6M 1.82%
1,772,038
-84,526
-5% -$2.22M
MRUS
15
DELISTED
Merus
MRUS
$59.2M 1.78%
1,001,073
-145,487
-13% -$7.05M
IDXX icon
16
Idexx Laboratories
IDXX
$44.9B
$58.2M 1.75%
119,500
-59,750
-33% -$30M
AGL icon
17
Agilon Health
AGL
$1.55B
$58.2M 1.75%
356,000
+2,600
+0.7% +$370K
DXCM icon
18
DexCom
DXCM
$29B
$56.7M 1.71%
500,000
-96,750
-16% -$12.2M
HUM icon
19
Humana
HUM
$43.9B
$55.1M 1.66%
147,408
– –
INSM icon
20
Insmed
INSM
$22.4B
$54.2M 1.63%
+808,356
New +$31.4M
RYTM icon
21
Rhythm Pharmaceuticals
RYTM
$7.31B
$52.6M 1.58%
1,280,493
-242,400
-16% -$9.68M
CLDX icon
22
Celldex Therapeutics
CLDX
$2.94B
$51.8M 1.56%
1,398,994
+26,809
+2% +$1.01M
PHR icon
23
Phreesia
PHR
$689M
$51.3M 1.54%
2,417,500
+52,500
+2% +$1.14M
EW icon
24
Edwards Lifesciences
EW
$49.4B
$50.8M 1.53%
550,000
-97,300
-15% -$8.62M
XENE icon
25
Xenon Pharmaceuticals
XENE
$6.1B
$49.6M 1.49%
1,272,877
+17,300
+1% +$692K
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

Rock Springs Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Rock Springs Capital Management held 123 positions worth $3.32B, down 16% from $3.94B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rock Springs Capital Management withdrew a net $442M in Q2 2024, closing 11 positions and reducing 28 holdings. Its most notable exit was Shockwave Medical, Inc. Common Stock, an estimated $44M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Rock Springs Capital Management opened a new position in Insmed worth $54.2M.

  • Rock Springs Capital Management's largest Q2 2024 buy was Insmed: 808,356 shares worth $54.2M.
  • Rock Springs Capital Management added most to Structure Therapeutics in Q2 2024, an estimated $24.1M increase.
  • Rock Springs Capital Management's biggest Q2 2024 reduction was Immunocore, cutting an estimated $99.4M.
  • Rock Springs Capital Management fully exited Shockwave Medical, Inc. Common Stock in Q2 2024, selling an estimated $44M.
  • Rock Springs Capital Management's ten largest holdings make up 36% of its $3.32B portfolio in Q2 2024.
  • Rock Springs Capital Management opened 10 new positions and closed 11 in Q2 2024.
  • Rock Springs Capital Management's portfolio value fell 16% quarter-over-quarter to $3.32B.

Based on Rock Springs Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.